TSX-002, a first-in-class oral formulation of unmodified testosterone.

[Nelson Vergel]

TesoRx Pharma LLC, a pharmaceutical company, has collected $10 million in Series B-1 funding to prepare for trials of its oral form of testosterone.

The Menlo Park-based company did not disclose specific investor information but did say existing and new backers participated. Founded in 2010, it has raised a total of $11.8 million and is led by CEO Ramachandran Thirucote.

TesoRx plans to use the capital to prepare for Phase 3 testing of oral testosterone drug TSX-002 and build out its commercial manufacturing facilities.

http://www.marketwatch.com/story/te...urologist-as-chief-medical-officer-2014-08-05

 

[Jasen Bruce]

It is liposomal which allows the hormone to enter the cell with being altered without a C-17 alkaloid. I am curious to see if has a timed release or will need to be dosed BID to keep levels stable.

 

[Dr. John Crisler]

It is liposomal which allows the hormone to enter the cell with being altered without a C-17 alkaloid. I am curious to see if has a timed release or will need to be dosed BID to keep levels stable.

So it is like Andriol then, an oral preparation which is absorbed via the gut lymphatics.

...and is not a very effective therapy, BTW.

 

[Nelson Vergel]

I bet it needs dosing more than once a day

http://tesorx.com/product-tsx.html

See the study (it says twice per day dosing)

http://clinicaltrials.gov/show/NCT01717768

 

[Dr. John Crisler]

I bet it needs dosing more than once a day

http://tesorx.com/product-tsx.html

See the study (it says twice per day dosing)

http://clinicaltrials.gov/show/NCT01717768

Yes. And to be taken with a fat load.

 

[Eli1947]

Yes. And to be taken with a fat load.

[TABLE="class: rightTable, width: 1097"] [TR] [TH="bgcolor: #428D99, align: left"] General Information[/TH]
[TABLE="class: generalInfo"] [TR] [TD="bgcolor: #DFDFDF"]Company	TesoRx Pharma LLC
Oral pro-liposomal formulation of unmodified testosterone

[TD]

[TD="bgcolor: #DFDFDF"]Description[/TD]

[TD="bgcolor: #DFDFDF"]Molecular Target[/TD]

[TD="bgcolor: #DFDFDF"]Mechanism of Action[/TD]

[TD="bgcolor: #DFDFDF"]Therapeutic Modality[/TD]

[TABLE="class: generalInfo"]
[TR]
[TD="bgcolor: #DFDFDF"]Latest Stage of Development[/TD]
[TD]Phase II[/TD]
[/TR]
[TR]
[TD="bgcolor: #DFDFDF"]Standard Indication[/TD]
[TD]Hypogonadism[/TD]
[/TR]
[TR]
[TD="bgcolor: #DFDFDF"]Indication Details[/TD]
[TD]Treat hypogonadism[/TD]
[/TR]
[TR]
[TD="bgcolor: #DFDFDF"]Regulatory Designation[/TD]
[TD][/TD]
[/TR]
[TR]
[TD="bgcolor: #DFDFDF"]Partner[/TD]
[TD][/TD]
[/TR]
[/TABLE]

[/TD]
[/TR]
[/TABLE]
[/TD]
[/TR]
[/TABLE]
120 and 240 mg BID , normal body produce 5-10 mg . wonder where most of the content go? out via feace? and how this formulation overcomes the first pass issue and testicular atrophy ?

 

[Nelson Vergel]

Liposomal formulations take advantage of the lymphatic system to spread the drug around the body.

Liposomal formulations for enhanced lymphatic drug delivery

 

[Eli1947]

Liposomal formulations take advantage of the lymphatic system to spread the drug around the body.

Liposomal formulations for enhanced lymphatic drug delivery

Thanks nelson. But what hapens to the big amount of the dose, just washed out with the feace?

 

[Mocha]

I'll bet a significant chunk of that $10 million will go into marketing.

 

[Eli1947]

I'll bet a significant chunk of that $10 million will go into marketing.

That money is just small estimate. First they have to succeed in their phase 3 clinical trials. Get their marketing license and then think about marketing expenses. 10M $ is under estimate for an operation to convince MD start prescribing us the new drug.